Received May 22, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| DTPPVHBHPB | DTAP+IPV+HIB+HEPB (VAXELIS) | MSP VACCINE COMPANY | 3 | U7767AA | RL |
| PNC15 | PNEUMO (VAXNEUVANCE) | MERCK & CO. INC. | UNK | — | IM / LL |
| RV5 | ROTAVIRUS (ROTATEQ) | MERCK & CO. INC. | UNK | — | PO / MO |
an inappropriate use due to VAXELIS being administered via the incorrect route/VAXELIS to a patient subcutaneous instead of intramuscular; This non-serious spontaneous safety report, with reference number 02733835 (interaction number: 02733830), was received by partner on 28-FEB-2025 and forwarded to UBC on 03-MAR-2025 from other health professional. Off-label classification was added due to Vaxelis being administered via incorrect route. Due to the nature of the event, the causality between the event 'an inappropriate use due to VAXELIS being administered via the incorrect route/VAXELIS to a patient subcutaneous instead of intramuscular' and Vaxelis was not applicable. Further information is expected. SIGNIFICANT FOLLOW-UP INFORMATION was received from a health professional on 28-MAR-2025. Due to the nature of the event, the causality between the event 'an inappropriate use due to VAXELIS being administered via the incorrect route/VAXELIS to a patient subcutaneous instead of intramuscular' and Vaxelis was not applicable. No further information is expected.
Normal baby; Prophylaxis